Cosmetic Ingredient Innovation In An Increasingly Cruelty-Free World; Is It Possible?

Visibility is low into the availability of new cosmetic ingredients since 2013, but there does appear to be a viable pathway for innovations to reach the EU market, despite the animal testing ban, as well as California, where similar prohibitions will go into effect in 2020. Still, industry’s best bet is to continue investing in alternative methods development and promoting their acceptance with regulators.

Young businessman thinking about ways to overcome business obstacle. Isolated with maze and copy space. Double exposure

Unilever PLC’s recent announcement that it will collaborate with Humane Society International in support of a global ban on cosmetics animal testing raises questions about the current state and future prospects for ingredient innovation.

According to the Personal Care Products Council, industry largely stopped testing finished cosmetic products on animals in the 1980s. Since...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By 

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By 

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.